NASDAQ:ANNX Annexon (ANNX) Stock Price, News & Analysis $7.34 -0.23 (-3.04%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Annexon Stock (NASDAQ:ANNX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Annexon alerts:Sign Up Key Stats Today's Range$7.22▼$7.6150-Day Range$5.41▼$7.6352-Week Range$1.71▼$8.40Volume1.07 million shsAverage Volume1.86 million shsMarket Capitalization$678.31 millionP/E RatioN/ADividend YieldN/APrice Target$15.80Consensus RatingBuy Company OverviewAnnexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Annexon Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks42nd Percentile Overall ScoreANNX MarketRank™: Annexon scored higher than 42% of companies evaluated by MarketBeat, and ranked 628th out of 1,001 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAnnexon has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAnnexon has only been the subject of 3 research reports in the past 90 days.Read more about Annexon's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Annexon are expected to decrease in the coming year, from ($0.97) to ($1.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Annexon is -5.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Annexon is -5.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnnexon has a P/B Ratio of 2.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Annexon's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.40% of the outstanding shares of Annexon have been sold short.Short Interest Ratio / Days to CoverAnnexon has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Annexon has recently increased by 26.12%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnnexon does not currently pay a dividend.Dividend GrowthAnnexon does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.40% of the outstanding shares of Annexon have been sold short.Short Interest Ratio / Days to CoverAnnexon has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Annexon has recently increased by 26.12%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.50 News SentimentAnnexon has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Annexon this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for ANNX on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows4 people have added Annexon to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Annexon insiders have sold 262.01% more of their company's stock than they have bought. Specifically, they have bought $37,504.00 in company stock and sold $135,768.00 in company stock.Percentage Held by Insiders12.67% of the stock of Annexon is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Annexon's insider trading history. Receive ANNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Annexon and its competitors with MarketBeat's FREE daily newsletter. Email Address ANNX Stock News HeadlinesInsider Selling: Annexon, Inc. (NASDAQ:ANNX) EVP Sells 5,408 Shares of StockOctober 18, 2024 | insidertrades.comAnnexon, Inc. Presents Promising Data from Phase 2 ARCHER StudyOctober 23 at 2:37 AM | americanbankingnews.comWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 24, 2024 | Porter & Company (Ad)Annexon Reports Promising Phase 2 Data For ANX007 In Geographic Atrophy Due To Dry AMDOctober 22 at 8:14 AM | markets.businessinsider.comAnnexon presents Phase 2 Vision Preservation data with ANX007 in dry AMDOctober 22 at 8:14 AM | msn.comWe're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash WiselyOctober 21 at 9:53 PM | finance.yahoo.comAnnexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 MeetingOctober 21 at 8:00 PM | globenewswire.comAnalysts Set Annexon, Inc. (NASDAQ:ANNX) Price Target at $15.80October 17, 2024 | americanbankingnews.comSee More Headlines ANNX Stock Analysis - Frequently Asked Questions How have ANNX shares performed this year? Annexon's stock was trading at $4.54 at the start of the year. Since then, ANNX stock has increased by 61.7% and is now trading at $7.34. View the best growth stocks for 2024 here. How were Annexon's earnings last quarter? Annexon, Inc. (NASDAQ:ANNX) posted its quarterly earnings results on Monday, August, 12th. The company reported ($0.23) EPS for the quarter, hitting analysts' consensus estimates of ($0.23). When did Annexon IPO? Annexon (ANNX) raised $150 million in an initial public offering on Friday, July 24th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Cowen served as the underwriters for the IPO. Who are Annexon's major shareholders? Annexon's top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.28%), Park Avenue Securities LLC (0.13%), Creative Planning (0.03%) and SG Americas Securities LLC (0.04%). Insiders that own company stock include Bain Capital Life Sciences Inv, Douglas Love, Michael Overdorf, Jennifer Lew, Ted Yednock and William H Carson. View institutional ownership trends. How do I buy shares of Annexon? Shares of ANNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Annexon own? Based on aggregate information from My MarketBeat watchlists, some other companies that Annexon investors own include NVIDIA (NVDA), MercadoLibre (MELI), Advanced Micro Devices (AMD), Meta Platforms (META), Barrick Gold (GOLD), CRISPR Therapeutics (CRSP) and Energy Transfer (ET). Company Calendar Last Earnings8/12/2024Today10/23/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ANNX CUSIPN/A CIK1528115 Webwww.annexonbio.com Phone650-822-5500Fax650-636-9773Employees60Year FoundedN/APrice Target and Rating Average Stock Price Target$15.80 High Stock Price Target$30.00 Low Stock Price Target$10.00 Potential Upside/Downside+115.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-134,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-44.68% Return on Assets-38.02% Debt Debt-to-Equity RatioN/A Current Ratio21.81 Quick Ratio21.81 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.20 per share Price / Book2.29Miscellaneous Outstanding Shares92,413,000Free Float92,268,000Market Cap$678.31 million OptionableOptionable Beta1.28 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (NASDAQ:ANNX) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annexon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annexon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.